Clinical Trials Logo

Urinary Bladder, Overactive clinical trials

View clinical trials related to Urinary Bladder, Overactive.

Filter by:

NCT ID: NCT00613327 Completed - Clinical trials for Urinary Bladder, Overactive

An Efficacy and Safety Study of Oxybutynin Chloride Oral Osmotic Therapeutic System (OROS) in Korean Overactive Bladder Participants

Start date: September 2007
Phase: Phase 4
Study type: Interventional

The objective of this study is to evaluate the efficacy of oxybutynin chloride oral osmotic therapeutic system (OROS) on patient-reported outcomes after 12 weeks of treatment by dose escalation in participants with overactive bladder.

NCT ID: NCT00611026 Completed - Overactive Bladder Clinical Trials

Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.

Start date: February 2008
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy and safety of fesoterodine in comparison to tolterodine and placebo for overactive bladder

NCT ID: NCT00603343 Completed - Clinical trials for Urinary Incontinence

Propiverine in Children Suffering From Non-Neurogenic Overactive Bladder and Urinary Incontinence

Start date: June 2004
Phase: Phase 3
Study type: Interventional

The study was conducted between 2004 and 2006 to prove efficacy and tolerability of the antimuscarinic propiverine compared to placebo in children suffering from non-neurogenic overactive bladder and urinary incontinence.

NCT ID: NCT00583219 Completed - Overactive Bladder Clinical Trials

Botulin-A Toxin Instillations and Overactive Bladder

Start date: March 2006
Phase: Phase 1/Phase 2
Study type: Interventional

The primary objective of this pilot study is to evaluate the safety and efficacy of direct instillations of Botulinum-A toxin/DMSO into the bladder via a catheter system as a means of treating women with symptoms of overactive bladder and secondary urinary incontinence. In doing so, we will focus on estimating the percentage of women who experience an improvement in their urinary incontinence symptoms at one month and three months following this novel instillation technique.

NCT ID: NCT00573508 Completed - Clinical trials for Urinary Bladder, Overactive

Study of VESIcare® In Overactive Bladder (OAB) Subjects to Evaluate Symptom Bother and Health Related Quality of Life

VIBRANT
Start date: August 2007
Phase: Phase 4
Study type: Interventional

Evaluate the effect of VESIcare® on symptom bother for subjects with OAB

NCT ID: NCT00564226 Completed - Overactive Bladder Clinical Trials

SSR240600C Treatment in Women With Overactive Bladder

BILADY
Start date: November 2007
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to evaluate the efficacy of SSR240600C in women with overactive bladder compared to placebo using tolterodine as a study calibrator.

NCT ID: NCT00561951 Completed - Overactive Bladder Clinical Trials

Dose-Finding Study To Evaluate The Efficacy, Tolerability And Safety Of Fesoterodine In Comparison To Placebo For Overactive Bladder.

Start date: November 2007
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of fesoterodine in comparison to placebo for overactive bladder.

NCT ID: NCT00553657 Completed - Overactive Bladder Clinical Trials

The Study To Test The Effect of Standardization Of Fluid Intake In Female Patients With Overactive Bladder

Start date: August 2007
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine if standardizing fluid intake in a clinic setting will reduce variability of individual voiding parameters and potentially serve as a way to limit patient exposure in the initial assessment of efficacy of compounds being developed for Overactive Bladder.

NCT ID: NCT00547378 Completed - Overactive Bladder Clinical Trials

InSite for Over Active Bladder

InSite - OAB
Start date: October 2007
Phase: Phase 4
Study type: Interventional

The purposes of this study are: 1. To provide evidence from a randomized controlled trial that InterStim Therapy provides better relief of symptoms of OAB than standard medical treatments in current use. 2. To fulfill the requirements of the FDA-mandated post-approval study of the safety of the tined lead using a minimally invasive approach.

NCT ID: NCT00546637 Completed - Clinical trials for Overactive Bladder Syndrome

Fesoterodine "add-on" Male Overactive Bladder Study

Start date: November 2007
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy and safety of fesoterodine on overactive bladder symptom improvement when added to ongoing alpha blocker treatment.